Overall, our work revealed a strong positive correlation between BRD4 overexpression status and chemoresistance in ovarian cancer, which could be explored to develop a prognostic strategy to predict a patient response to platinum/taxane-based chemotherapy. Here, BRD4 is linked to ovarian carcinoma.